14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CVM vs ADVM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Adverum Biotechnologies, Inc. (ADVM) captures the overall head-to-head institutional edge over Cel-Sci Corporation (CVM) on higher Unified Composite conviction (62.4/100 BUY vs. 56.6/100 HOLD) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow, Options & Positioning), while CVM wins 3–2 across the 6-pillar growth and valuation breakdown. CVM trades at $1.59 (23.0x Forward P/E, 0.0% operating margin) versus ADVM at $4.36 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: ADVM earns the overall head-to-head edge with a stronger Unified Composite Score (62.4/100 BUY vs. CVM 56.6/100 HOLD) and 1.04β · 17% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile ADVM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 57.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CVM vs ADVM. Trailing 12-month operating profitability (CVM 0.0% vs ADVM 0.0%) and valuation multiples (CVM 23.0x vs ADVM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Biological Products, (No Disgnostic Substances) Operator
Competes within the Biological Products, (No Disgnostic Substances) value chain with $91.8M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CVM vs ADVM Key Questions & Quantitative Answers
As of Nov 16, 2026, Adverum Biotechnologies, Inc. (ADVM) captures the overall head-to-head institutional edge over Cel-Sci Corporation (CVM) on higher Unified Composite conviction (62.4/100 BUY vs. 56.6/100 HOLD) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow, Options & Positioning), while CVM wins 3–2 across the 6-pillar growth and valuation breakdown. CVM trades at $1.59 (23.0x Forward P/E, 0.0% operating margin) versus ADVM at $4.36 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ADVM earns the overall head-to-head edge with a stronger Unified Composite Score (62.4/100 BUY vs. CVM 56.6/100 HOLD) and 1.04β · 17% Vol risk profile, whereas CVM leads top-line expansion (-62.7% YoY revenue growth, 1.12x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CVM is currently in a Breakdown options structure phase (RSI 57.1); meanwhile ADVM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 57.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CVM leads the Growth & Scale pillar: CVM posts -62.7% YoY revenue growth and +0.0% YoY earnings growth on $28,558 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ADVM at -70.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, CVM generates $28,558 in USD-normalized revenue versus N/A for ADVM. In operating R&D and SG&A reinvestment, CVM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ADVM.
CVM screens cheaper on headline valuation multiples. CVM trades at 23.0x Forward P/E, 23.0x Trailing P/E, 1.12x PEG, and N/M EV/Revenue (unreported FCF margin), whereas ADVM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CVM (-252.5% ROE) versus ADVM (-417.8% ROE) capital efficiency.
In options market volatility and institutional positioning, CVM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.65β · 120% Vol realized risk). By comparison, ADVM carries 30.2% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 17% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.